An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases

NCT07174843 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Inflammatory Myopathies(IIM)
Immune Thrombocytopenia(ITP)
Systemic Lupus Erythematosus(SLE)

Interventions

BIOLOGICAL: CD19/CD22/BCMA CAR-T cells(BZE2204)

Sponsor

Shanghai Cell Therapy Group Co.,Ltd